KoBioLabs has been growing earnings at an average annual rate of 20.9%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 50.8% per year.
How KoBioLabs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A348150 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
71,212
-3,728
53,619
7,200
31 Dec 25
69,292
-6,330
52,591
7,572
30 Sep 25
71,826
-6,547
52,977
7,878
30 Jun 25
69,479
-8,281
51,830
7,772
31 Mar 25
70,777
-5,682
50,226
7,547
31 Dec 24
68,359
-5,298
46,134
6,905
30 Sep 24
61,290
-9,471
42,124
9,694
30 Jun 24
52,081
-11,096
36,658
10,739
31 Mar 24
40,321
-12,608
31,240
12,333
31 Dec 23
33,138
-13,853
27,321
14,262
30 Sep 23
29,303
-16,091
24,856
13,506
30 Jun 23
24,119
-17,122
21,712
14,838
31 Mar 23
18,249
-21,739
17,813
14,593
31 Dec 22
11,606
-21,921
13,675
14,198
30 Sep 22
5,809
-17,940
9,118
13,575
30 Jun 22
3,973
-17,851
7,223
12,766
31 Mar 22
3,233
-16,061
6,003
13,447
31 Dec 21
2,893
-15,382
5,580
12,496
30 Sep 21
4,936
-17,289
6,845
11,686
30 Jun 21
5,219
-15,509
6,792
10,413
31 Mar 21
5,067
-12,945
6,593
9,171
31 Dec 20
4,591
-55,072
5,894
8,882
30 Sep 20
1,752
-51,005
4,178
7,777
30 Jun 20
945
-50,232
3,912
7,578
31 Mar 20
685
-68,745
3,513
5,790
31 Dec 19
577
-44,067
3,153
4,319
31 Dec 18
64
-8,382
1,523
717
Quality Earnings: A348150 is currently unprofitable.
Growing Profit Margin: A348150 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A348150 is unprofitable, but has reduced losses over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare A348150's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A348150 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).
Return on Equity
High ROE: A348150 has a negative Return on Equity (-8.75%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/19 16:55
End of Day Share Price
2026/08/19 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KoBioLabs, Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.